Caine Graham J, Lip Gregory Y H, Stonelake Paul S, Ryan Peter, Blann Andrew D
Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.
Thromb Haemost. 2004 Jul;92(1):185-90. doi: 10.1160/TH03-11-0679.
In health, haemostasis and angiogenesis are tightly regulated processes, but may become deregulated in cancer. Recent evidence suggests that platelet activation may link these processes as platelets can release angiogenic factors such as vascular endothelial growth factor (VEGF). Furthermore, inflammation has also been implicated in regulating both coagulation and angiogenesis, possibly by activating platelets directly and increasing, for example, plasma fibrinogen. We hypothesized relationships between plasma markers of the processes in two common forms of cancer. Plasma levels of VEGF (reflecting angiogenesis), soluble P-selectin, (marking platelet activation), tissue factor [TF], fibrinogen and fibrin D-dimer (coagulation markers), and serum levels of IL-6 (inflammation) were measured by ELISA in 30 patients with biopsy-proven breast cancer, 30 patients with biopsy-proven prostate cancer, and 30 age- and sex-matched controls for each group. Prostate specific antigen was also measured in the men. Release of VEGF from IL-6 stimulated platelets was assessed by ELISA. Plasma levels of IL-6 (P <0.02), VEGF, soluble P-selectin, fibrinogen, and fibrin D-dimer (all p <0.01) were significantly raised in breast cancer, whereas VEGF, soluble P-selectin, fibrin D-dimer (all p <0.01) and fibrinogen (p <0.05) were significantly raised in prostate cancer. Significant correlations were found between IL-6 and VEGF (p <0.01), and IL-6 and soluble P-selectin (p = 0.038) in breast cancer. Further experiments demonstrated an in vitro IL-6 induced dose-dependent release of VEGF from platelets. In conclusion, strong relationships between IL6 and VEGF, but not with coagulation or platelet markers, and release of VEGF from IL-6 stimulated platelets, suggest a role for inflammation and platelets in angiogenesis.
在健康状态下,止血和血管生成是受到严格调控的过程,但在癌症中可能会失调。最近的证据表明,血小板激活可能将这些过程联系起来,因为血小板可以释放血管生成因子,如血管内皮生长因子(VEGF)。此外,炎症也被认为参与调节凝血和血管生成,可能是通过直接激活血小板并增加例如血浆纤维蛋白原。我们推测了两种常见癌症中这些过程的血浆标志物之间的关系。通过酶联免疫吸附测定法(ELISA)测量了30例经活检证实为乳腺癌的患者、30例经活检证实为前列腺癌的患者以及每组30例年龄和性别匹配的对照者的血浆中VEGF水平(反映血管生成)、可溶性P-选择素(标记血小板激活)、组织因子[TF]、纤维蛋白原和纤维蛋白D-二聚体(凝血标志物),以及血清中IL-6水平(炎症)。还对男性患者测量了前列腺特异性抗原。通过ELISA评估了IL-6刺激的血小板释放VEGF的情况。乳腺癌患者的血浆IL-6水平(P <0.02)、VEGF、可溶性P-选择素、纤维蛋白原和纤维蛋白D-二聚体(均P <0.01)显著升高,而前列腺癌患者的VEGF、可溶性P-选择素、纤维蛋白D-二聚体(均P <0.01)和纤维蛋白原(P <0.05)显著升高。在乳腺癌中,发现IL-6与VEGF之间存在显著相关性(P <0.01),IL-6与可溶性P-选择素之间存在显著相关性(P = 0.038)。进一步的实验表明,体外IL-6可诱导血小板剂量依赖性释放VEGF。总之,IL-6与VEGF之间存在密切关系,但与凝血或血小板标志物无关,且IL-6刺激的血小板可释放VEGF,这表明炎症和血小板在血管生成中发挥作用。